razoxane has been researched along with Cancer of Head in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SR; Bricker, LJ; Natale, RB; Wheeler, RH | 1 |
| Bruno, S; Macdonald, JS; Marsoni, S; Penta, J; Poster, DS | 1 |
| Bellet, RE; Catalano, RB; Creech, RH; Engstrom, PF; Paul, AR; Shah, MK | 1 |
1 trial(s) available for razoxane and Cancer of Head
| Article | Year |
|---|---|
Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Interactions; Head and Neck Neoplasms; Humans; Lymphoma; Mice; Neoplasm Metastasis; Neoplasms; Piperazines; Razoxane | 1980 |
2 other study(ies) available for razoxane and Cancer of Head
| Article | Year |
|---|---|
Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Piperazines; Razoxane | 1984 |
Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Piperazines; Razoxane | 1982 |